National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2017

Abstract

The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of persons aged 11–12 years with human papillomavirus (HPV) vaccine, quadrivalent meningococcal conjugate vaccine (MenACWY), and tetanus and reduced diphtheria toxoids and acellular pertussis vaccine (Tdap). A booster dose of MenACWY is recommended at age 16 years (1), and catch-up vaccination is recommended for hepatitis B vaccine (HepB), measles, mumps, and rubella vaccine (MMR), and varicella vaccine (VAR) for adolescents whose childhood vaccinations are not up to date (UTD) (1). ACIP also recommends that clinicians may administer a serogroup B meningococcal vaccine (MenB) series to adolescents and young adults aged 16–23 years, with a preferred age of 16–18 years (2). To estimate U.S. adolescent vaccination coverage, CDC analyzed data from the 2017 National Immunization Survey–Teen (NIS-Teen) for 20,949 adolescents aged 13–17 years.* During 2016–2017, coverage increased for ≥1 dose of HPV vaccine (from 60.4% to 65.5%), ≥1 dose of MenACWY (82.2% to 85.1%), and ≥2 doses of MenACWY (39.1% to 44.3%). Coverage with Tdap remained stable at 88.7%. In 2017, 48.6% of adolescents were UTD with the HPV vaccine series (HPV UTD) compared with 43.4% in 2016.† On-time vaccination (receipt of ≥2 or ≥3 doses of HPV vaccine by age 13 years) also increased. As in 2016, ≥1-dose HPV vaccination coverage was lower among adolescents living in nonmetropolitan statistical areas (MSAs) (59.3%) than among those living in MSA principal cities (70.1%).§ Although HPV vaccination initiation remains lower than coverage with MenACWY and Tdap, HPV vaccination coverage has increased an average of 5.1 percentage points annually since 2013, indicating that continued efforts to target unvaccinated teens and eliminate missed vaccination opportunities might lead to HPV vaccination coverage levels comparable to those of other routinely recommended adolescent vaccines.

Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening

“…These rates have been increasing about 5% per year. Although the increase in encouraging, there is still much work to be done …”

Dental professionals' knowledge, attitudes, and practice behaviors related to human papillomavirus vaccination

“…To reach herd immunity against the HPV types included in the vaccine, http://healthypeople.gov (Office of Disease Prevention and Health Promotion) aims for 80 percent of all 13–15 year‐old adolescents to complete the vaccine series . However, according to the Centers for Disease Control and Prevention, among age‐eligible youth nationwide in 2017, 65 percent of teens had received at least a single dose of the vaccine . Similarly, in Arizona, 65 percent of adolescents aged 13–17 years completed 1 dose, while 53 percent completed the entire vaccine series .…”

Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008–2015

“…In 2015, a 9‐valent HPV vaccine (9vHPV), which targets HPV16, 18 and five additional HR‐HPV types (31/33/45/52/58) was licensed; since 2017, it has been the only vaccine available in the US . Vaccine coverage has gradually increased in the US since vaccine introduction, and by 2017, 69% of adolescent females aged 13–17 years had received at least one dose . The incidence of cervical precancers (CIN grades 2, 2/3 or 3, or AIS, referred to as CIN2+) has declined among screened women since vaccine introduction, but trends in the incidence of AIS specifically in the vaccine era have not been described.…”